Proteocyte Announces Mark Hammar as new CEO

Toronto, ON; January 19, 2022 – Proteocyte AI, a company dedicated to producing a range of technological solutions that predict a patient’s risk of developing oral cancer, is pleased to announce the appointment of Mark Hammar as Chief Executive Officer, effective immediately.

Mr. Hammar is taking over the position previously held by Dr. Anthony Morlandt, who now assumes the role of Chief Medical Officer for U.S. Operations within the company.

This change in leadership was made in order to fully capitalize on Mr. Hammar’s extensive commercial experience in the healthcare field, bringing start-ups from conception to commercialization. It also helps Dr. Morlandt focus his vast clinical knowledge on the areas of the technology that will be of particular interest to fellow physicians as they seek to improve patient outcomes. Dr. Morlandt and Steve Arless, Executive Chairman, presented this succesion plan during the Q4 2021 Shareholders’ Meeting held via Zoom, as part of the Company’s strategy to raise capital and commercialize the Straticyte™ test in the United States and Canada.

Mr. Hammar’s background includes extensive work with innovative medicines, medical devices and genomics. He most recently held the position of Country Manager, Canada for Myriad Genetics Inc. and has spent much of the last 10 years bringing start-ups to market within the Canadian healthcare space.

“I’m excited to have this opportunity to lead Proteocyte as we get closer to full commercialization of our technology,” says Mr. Hammar. “Dr. Morlandt has steered the company in a great direction and we will continue to maintain our momentum. Together, we continue to pursue all of our commercialization milestones during this exciting “comeback” phase of the company, beginning in late 2020.”

About Proteocyte

Proteocyte is a personalized medical diagnostics company located in MaRS Centre, Toronto, ON. Proteocyte’s product helps tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte™, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.